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Pancreatic islet transplantation is a promising treatment option for Type 1 Diabetics, offering improved 
glycaemic control through restoration of insulin production and freedom from life-threatening 
hypoglycaemic episodes. Implementation of the Edmonton protocol in 2000, a glucocorticoid-free 
immunosuppressive regimen has led to improved islet transplantation success. >50% of islets are lost post-
transplantation primarily through cytokine-mediated apoptosis, ischemia and hypoxia. Gene therapy 
presents a novel strategy to modify islets for improved survival post-transplantation. Current islet gene 
therapy approaches aim to improve islet function, block apoptosis and inhibit rejection. Gene transfer 
vectors include adenoviral, adeno-associated virus, herpes simplex virus vectors, retroviral vectors 
(including lentiviral vectors) and non-viral vectors. Adeno-associated virus is currently the best islet gene 
therapy vector, due to the vectors minimal immunogenicity and high safety profile. In animal models, using 
viral vectors to deliver genes conferring local immunoregulation, anti-apoptotic genes or angiogenic genes 
to islets can significantly improve islet survival in the early post-transplant period and influence long term 
engraftment. With recent improvements in gene delivery and increased understanding of the mechanisms 
underlying graft failure, gene therapy for islet transplantation has the potential to move closer to the clinic 



























Type 1 diabetes (T1D) is a chronic, life-long autoimmune disease in which the immune system destroys the 
insulin-producing β-cells within the pancreatic islets. Islet transplantation is a promising treatment 
approach for T1D, maintaining blood glucose levels to an extent that has not been possible with traditional 
insulin injections [1, 2]. The potential of islet transplantation as a treatment for T1D was demonstrated in 
2000, with the introduction of a steroid-free immunosuppressive protocol, termed the Edmonton Protocol 
[3]. To date, more than 700 diabetic patients have received an islet transplant [4], and there is considerable 
clinical evidence to suggest that islet transplantation can improve glycaemic control above that conferred 
by exogenous insulin treatment. The benefit is particularly significant for diabetic patients that suffer 
hypoglycaemic unawareness [5]. 
 
A major limitation to the success of clinical islet transplantation is the early loss of islet mass 24 – 48 hours 
post-transplantation. Immediately following transplantation, islets face a number of environmental 
challenges and stresses, including cytokine assault and inflammation, which lead to significant islet 
apoptosis. Pancreatic islets are one of the most heavily vascularized structures in the body and disruption of 
the capillary network during isolation results in islet ischemia and hypoxia. Islets are also highly 
immunogenic cellular structures, a property which leaves them vulnerable to the effects of alloimmunity 
and recurrence of anti-islet autoimmunity [6].  
 
The development of highly efficient viral vectors capable of transferring useful genes to human cells 
has led to the concept of gene therapy, a therapeutic strategy that could be used for a variety of 
metabolic disorders and autoimmune diseases [7]. Early transplant stresses such as apoptosis and acute 
rejection may potentially be overcome through the use of ex vivo gene therapy strategies to deliver 
immunomodulatory, anti-apoptotic or angiogenic genes to the islets to improve post-transplant islet 
viability, engraftment, survival and resistance to rejection. 
 
This review will discuss various viral-mediated gene transfer strategies that have been employed to 
improve islet survival in preclinical models, including the delivery of anti-apoptotic and angiogenic 
genes, as well as those conferring local immunoregulation to the islet graft.  
 
Viral-Mediated Gene Transfer to Pancreatic Islets 
 
There are four major classes of viral vectors utilized in gene therapy, adenoviruses (AdV), adeno-
associated viruses (AAV), herpes simplex viruses and retroviruses (including lentiviruses) as shown in 
table 1. A number of studies have demonstrated the ability of these vectors to infect pancreatic islets of 
both human and animal origin [8-11]. 
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Commonly used gene delivery viral vectors. Table 1 
Type Adenovirus Adeno-associated virus Herpes Simplex Virus Retrovirus Lentivirus 
Packaging Capacity Medium (≤7.5 kilo base pairs) Low (≤4.5 kilo base pairs) Large (≥30  kilo base pairs) Medium (≤7 kilo base pairs) Medium (≤8 kilo base pairs) 
Duration of 
expression 
Transient Stable, long-term Stable, long-term Transient, however stability 
of expression from newer 
generation vectors is 
markedly improved to 
produce sustained expression 
Stable, long-term 
Immunogenicity High Low Low Low Low 
Repeated dosing Not possible Possible Possible Possible Possible 
Clinical Trials Yes Yes Yes Yes Yes 
Advantages Infects both dividing and non-
dividing cells, provides 
transient expression, 
particularly high short term 
expression, generates high 
titer viral stocks 
Infects both dividing and 
non-dividing cells, 
integrates into host 
genome, provides long-
term expression in vivo, 
elicits minimal immune 
response, generates high 
viral titers 
Large genome, non-
pathogenic, unable to 
reactivate, broad host range, 
persists long-term. 
Integrates into host genome, 
provides long-term expression 
and stable transduction 
Infects both dividing and 
non-dividing cells, genome 
integration, long-term 
expression 
Disadvantages Immunogenic, cause mild 
respiratory disease in humans 
Requires helper virus, slow 
expression onset, 
inefficient large-scale virus 
production, small genome 
limiting packaging capacity 
Potentially provoke antiviral 
responses against HSV-
infected cells 
Low efficiency in vivo, risk of 
insertional mutagenesis, low 
titer, host range restricted to 
dividing cells only 






The majority of AdV vectors are based on human serotypes 2 and 5 which are known to cause a mild 
respiratory disease and are non-oncogenic [12]. More clinical trials utilise AdV-based vectors than any 
other vector currently available [13] and the applicability and safety of AdV for gene therapy has been 
studied extensively [14-17]. 
 
AdV vectors can trigger the innate immune response through the induction of type I interferons [18, 
19]. This reduces the efficacy of gene transfer by eliminating expression of the genes encoded by the 
construct [20, 21]. In addition, patients treated with AdV constructs may suffer complications or even 
death [20, 22, 23]. Heavily immunosupressed patients are especially susceptible to severe AdV 
complications from treatment. 
 
A major advantage of AdV for gene therapy is that they possess a medium size genome of ≤7.5 kilo 
base (kb) pairs, which allows them to accommodate large or multiple transgenes. In addition, AdV 
generate high titer viral stocks (1012-1013 virus particles per ml), and provide high transduction 
efficiency. AdV infect both dividing and non-dividing cells, an important property when considering 
the transduction of senescent islet cells. The AdV genome is extra chromosomal, which significantly 
minimises the risk of insertional mutagenesis resulting from insertion of exogenous DNA into the 
genome [24]. AdV requires the coxsackie/adenovirus receptor (CAR), heparin sulphate, αvβ5 integrin 
and αvβ5 adherin for infection [24, 25]. CAR has been found on murine islets and β-cell lines, which 
may explain the relatively high efficacy of AdV transduction in islets [26]. Successful AdV infection of 
rodent pancreatic islets has been described by many research groups [27-30]. Safety studies in human 
islets demonstrated that AdV infection does not diminish β-cell viability or function in vitro [28, 30, 
31]. Leibowitz and colleagues [32] compared the three major classes of viral vectors, and found AdV 
to be the most effective vector for infection of intact islets.  
 
Adeno-Associated Virus Vectors 
 
AAV are small, non-enveloped single-stranded DNA viruses that require a helper-virus for productive 
infection [33].  AAV possess many properties that make them attractive for use as gene transfer vectors 
in gene therapy. AAV vectors infect quiescent cells, elicit a minimal immune response and are non-
pathogenic [34]. In addition, AAV achieve targeted and stable expression through site-specific 
integration, and possess low mutagenic and oncogenic potential [35]. AAV may integrate randomly 
into the host genome at sites of double-stranded DNA breaks [36] but display low frequency of random 





A major limitation of AAV vectors is that the maximum size of the gene insert is ≤4.5 kb pairs (smaller 
than AdV). This limits the potential for inserting multiple genes. AAV gene transfer of the cystic 
fibrosis transmembrane regulator has progressed to phase II trials in cystic fibrosis patients [34] and 
other AAV vectors have been evaluated as candidates for Hemophilia A and B treatment with gene 
therapy in both preclinical and clinical models [38].  
 
The ability of AAV to transduce a given cell type depends on the presence of membrane-associated 
heparan sulfate proteoglycan (HSPG) receptors [39] and co-receptors including αvβ5 integrin 
heterodimers, fibroblast growth factor receptor type 1 and c-met [40-43]. Kahn and colleagues [44] 
have identified the presence of HSPG on human islets. Transduction of islets with AAV has been 
shown by a number of groups [45-49]. Wang and colleagues [45] revealed distinct AAV islet 
transduction efficiency and gene transfer patterns between different vector serotypes and administration 
routes. Local intra pancreatic ductal administration of AAV6 showed the best transduction efficiency in 
β-cells. Intraductal and intraperitoneal administration of AAV8 revealed efficient transduction of both 
exocrine acinar cells and endocrine β-cells. The transduction efficiency of AAV8 is attributable to the 
distinct properties of this viral serotype, including its receptor, laminin, which is highly expressed in 
the pancreas, and facilitates viral entry into the pancreatic cells [46]. Despite a number of AAV 
serotype studies, the optimal serotype for islet infection is yet to be determined. 
Herpes Simplex Viral Vectors 
Herpes Simplex Virus (HSV) is a double-stranded linear DNA virus, 152 kb in size with a virion 
structure consisting of an envelope, tegument, capsid and core. HSV-1 forms part of the larger 
Herpesviridae family, and is the most frequently used herpes virus for gene transfer. HSV-1 infection 
is common in the general population, manifesting itself as cold-sores however in rare cases it can cause 
encephalitis [50].   
 
HSV-1 possesses a broad host range with the ability to infect many cell types. In particular, HSV-1 
vectors provide efficient transduction and gene expression within the nervous system [53-55]. 
Therefore, most of the research utilizing HSV-1 vectors has focused on therapies to target neurological 
diseases. The large genome of HSV-1 (≥30 kb pairs) allows the vector to accommodate large or 
multiple transgenes or regions including regulatory elements or promoters [51]. In addition, the HSV-1 
vector remains as an extrachromosomal episome, which decreases the likelihood of insertional 
mutagenesis within the host’s genome [52]. These properties combined with the ability of HSV-1 to 
infect non-dividing cells makes it a suitable vector system for use in islet gene therapy [51]. 
 
To date, there have been a limited number of studies demonstrating the ability of HSV-1 to infect 
pancreatic islets [62, 63]. Liu and colleagues [63] have shown that murine islets and a β-cell line were 
efficiently transduced by a HSV vector, and that cytokine-mediated β-cell apoptosis was blocked by 
transduction with an anti-apoptotic Bcl-2 expressing HSV-1 vector. 
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In order for HSV to become a viable option for clinical islet gene therapy two major disadvantages of 
this vector system must be overcome. Firstly, HSV vehicles can be toxic and have the ability to 
provoke potent antiviral responses against HSV-infected cells [64]. Secondly, HSV provide only short 
transgene expression. New generation, completely defective HSV vectors are currently being 
developed that could allow these vector obstacles to be overcome [65]. 
 
Retroviral vectors 
The first human gene therapy clinical trial was based on a retroviral vector, for correction of adenosine 
deaminase deficiency. In this study, both integrated retroviral vector and adenosine deaminase gene 
expression persisted for several years [66]. Retroviral vectors possess many advantages over other viral 
vectors for long-term treatment or correction of gene defects. Retroviral vectors allow for an insert size 
of up to 7 kb pairs and they integrate into the target cell genome, resulting in sustained gene 
expression. 
There are over 250 currently approved retroviral gene therapy clinical trials, accounting for nearly 30% 
of the total clinical trials approved worldwide [67]. However, retroviral vectors are unable to infect 
non-dividing cells, such as islets, severely limiting their potential for use in islet gene therapy. 
Lentiviruses however are a subset of retroviruses with the ability to infect non-dividing cells and are 
therefore a logical retroviral candidate for use in islet gene therapy [68-70]. The first successful 
transduction of adult human pancreatic β-cells was performed using lentivirus, by Ju and colleagues in 
1998 [11]. One study comparing infection of intact islets found that while no infection was achieved 
using retroviral vectors, up to 25% of the β-cells could be infected with lentivirus [32]. 
Lentiviral vectors have been shown to efficiently transduce dispersed islets [11], monolayer cultures of 
islets [32] and intact islets [10, 71-74] from different species including human. Giannoukakis and 
colleagues [10] demonstrated the ability of lentiviral vectors to transduce islets at a comparable 
efficiency to AdV without the drawbacks of immunogenicity. Furthermore, lentiviral vectors can 
efficiently transduce whole islets [9] and lentivirus transduced rat islets display no changes in islet 
morphology or function [75], further supporting their use in islet gene therapy.  
Non-Viral-Mediated Gene Transfer to Pancreatic Islets  
Various non-viral islet transduction strategies such as bacterial plasmids, cationic lipid- and polymer-
based carriers, gene gun technology and calcium phosphate precipitation have been considered [76-84], 
with low transduction efficiency being the major obstacle reported to date.  
A number of research groups [84-86] have investigated the use of protein transduction technology in 
islet gene therapy. This is a novel technique which allows delivery of specific proteins or peptides 
fused to small cell-penetrating peptides known as protein transduction domains to cells or tissues [87]. 
Delivery of a JNK inhibitory peptide via this system prevented islet apoptosis following isolation and 
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improved islet graft function. Furthermore, an NF-κB inhibitor infused into the mouse pancreatic duct 
prior to isolation yielded islets with enhanced viability [88].  
Non-viral vectors offer several advantages over viral vectors including high clinical safety, no 
immunogenicity and ease of production. Despite this, non-viral vectors provide low islet transduction 
efficiency, owing to both the large size of the islets [83]  and the diffusive barrier created by the islet 
nuclear membrane [78]. In addition, non-viral vectors offer only transient gene expression and require 
high doses [77, 81, 82] when compared to viral vectors. At present, despite extensive investigation of 
non-viral approaches for use in islet gene therapy, no studies have progressed to clinical trials.  
Summary  
The four groups of viral gene therapy vectors described have specific strengths and weaknesses 
regarding their usefulness for islet transplantation. AAV have no known disease association and 
provide site-specific integration of DNA, whereas other viruses such as lentivirus insert randomly into 
the host genome and exhibit preference for integration at active transcription sites, generating concern 
regarding risk of insertional mutagenesis [89]. New-generation integration-deficient lentiviral vectors 
(IDLVs) have been developed that exhibit a reduced risk of causing insertional mutagenesis [90] and 
therefore may be a useful vector to pursue in future gene therapy studies. 
Vectors such as AdV that carry large inserts may be favoured over others for some applications, 
however the safety concerns surrounding AdV, herpes simplex virus and lentiviral vectors limit their 
clinical potential. Non-viral vectors offer high clinical safety over their viral vector counterparts, but 
they have the disadvantage of very low islet transduction compared to AdV vectors which provide very 
high islet transduction efficiency [10]. Of the currently available viral vectors, AAV provides the best 
gene therapy tool available for islet transplantation due to its minimal immunogenicity, safety profile 
and its ability to produce high viral titers relevant for clinical use. However, expanded understanding of 
AAV biology and differences between vector serotypes is required to lead to improved and varied 
clinical applications for AAV gene therapies in the future. 
Gene Transfer Strategies to Improve Islet Transplantation 
There are a number of cellular processes that may be targeted by gene therapy to improve the outcomes 
of islet transplantation. Once the appropriate gene therapy vector has been selected, this must be paired 
with the optimal gene to be delivered. Effective therapy may result from the overexpression of an 
active protein, or the inhibition of a deleterious gene. Genes that are likely to be useful for islet 
transplantation fall into three main categories: immunomodulatory, anti-apoptotic and angiogenic 
(summarized in Fig. (1)). Numerous studies have investigated the potential of gene therapy for islet 






Gene transfer strategies to improve islet transplantation. Figure 1 
Three areas of islet cell biology that are currently being targeted by gene therapy are depicted. 
Immunomodulatory strategies (upper left panel) include co-stimulation blockade with CTLA4Ig and 
production of immunomodulatory interleukin-10 (IL-10) and interleukin-4 (IL-4). Anti-apoptotic 
approaches (upper right panel) target extrinsic (via stimulation of death receptors) and intrinsic (release 
of apoptotic factors by mitochondria) apoptosis pathways in the β-cell.  Bcl-XL and Bcl2 (blue box) 
block pro-apoptotic proteins while XIAP (white box) directly inhibits caspases 3 and 9. Angiogenic 
(lower panel) factors VEGF, HGF, FGF and matrix metalloproteinases are induced during hypoxia and 
can be therapeutically overexpressed to enhance revascularization. Antisense blockade of angiostatic 
TSP-1 (white hexagons) improves the potency of proangiogenic factors. Figure represents a whole 
islet, with constituent α- (blue; glucagon-producing), β- (green; insulin-producing) and PP-(white; 
pancreatic polypeptide-producing) cells depicted in the upper left panel. Enlarged representations of 
infiltrating immune cells are shown (APC = antigen presenting cell; Ag = islet-specific antigen). 
10 
 
Genes delivered to pancreatic islets using viral vectors. Table 2 
Pathway Transgene Vector Comment 
CTLA4Ig Adenovirus Expression of CTLA4Ig in islets can prolong islet graft survival [93-96] 
 Lentivirus Islets transduced with CTLA4Ig prolong graft survival in a rat to mouse transplantation model [74] 
Interleukin-10 Adeno-associated virus IL-4 transduced islets resulted in impaired metabolic function in recipient mice and 
normoglycaemia in only 1/7 mice [102]. Viral IL-10 introduced systemically sustained suppression 
of autoimmune responses and prolonged islet allograft survival [101] 
Interleukin-4 Adeno-associated virus AAV-8 mediated IL-4 gene transfer to islets prevented the onset of diabetes in NOD mice [103] 
Immunomodulation 
CTLA4Ig/CD40Ig Adenovirus Results in simultaneous blockade of co-stimulation pathways [97]  
Bcl-2 Adenovirus Over expression of Bcl-2 in islet cells failed to prevent cytokine induced toxicity [110] and reduce 
inflammation in porcine islets [112]  
 Lentivirus Bcl-2 transduction of an pancreatic β-cell line provided protection against apoptosis induced by 
various stimuli including hypoxia and pro-inflammatory cytokines and corrected hyperglycaemia 
for several months when transplanted under the kidney capsule of diabetic C3H mice [111] 
 Herpes Simplex Virus-1 Cytokine-mediated beta-cell apoptosis was blocked by transduction with an Bcl-2 expressing 
HSV-1 vector [63] 
Bcl-XL Adenovirus Bcl-XL transduction of a rat insulinoma cell line blocked cytokine induced apoptosis [114] 
Anti-Apoptotic 
XIAP Adenovirus Adenoviral-XIAP transduced βTC-Tet cells and human islets are highly resistant to hypoxia and 
cytokine induced apoptosis in vitro and βTC-Tet cells transplanted into SCID mice successfully 
reverse diabetes in 3 days compared to 21 for control cells [121-123] 
VEGF Adenovirus Rat islet grafts with elevated VEGF production exhibited significantly increased microvasculature, 
insulin content and reversed hyperglycaemia in diabetic mice [136] 
Angiogenic 
HGF Adenovirus Co-expression of hHGF and hIL-1Ra led to significant decrease in caspase-3 induced in human 
islets by cytokine challenge in vitro. Transduction of human islets improved the outcome of islet 
transplantation [137]. Pre-transplant islet gene therapy with HGF markedly improved islet 
transplant outcomes even in the setting of immunosuppressant-induced insulin resistance and β-




A variety of immunomodulatory gene transduction strategies have been employed to confer islet 
transplant survival, by controlling or limiting local immune-mediated destruction.  
CTLA4Ig 
 
CTLA4Ig is an immunomodulatory molecule that is composed of the binding domain of human 
cytotoxic T lymphocyte associated antigen-4 attached to the Fc portion of human IgG1. CTLA4Ig 
binds to CD80/86 and blocks costimulatory signaling through CD28 thus preventing T cell activation - 
a process important for maintenance of the inflammatory response. As an immunosuppressive strategy, 
CTLA4Ig has been approved for the treatment of rheumatoid arthritis with the therapeutic drug 
Abatacept [91]. A second generation drug, Belatacept, is in phase III clinical trial for renal 
transplantation [92]. 
 
Feng and colleagues [93] demonstrated prolonged islet graft survival when AdV-CTLA4Ig transduced 
rat islets were transplanted into streptozotocin treated mice. A number of studies have shown that 
systemic administration of CTLA4Ig is more effective than local delivery in both allograft and 
xenograft models of islet transplantation [94] [95] This is probably reflective of the action of CTLA4Ig 
which blocks antigen presentation during T cell activation, a process likely to occur at a distant site 
such as the regional lymph nodes. 
 
Another costimulatory pathway, CD40/CD40L has also been targeted using gene therapy to prolong 
graft survival. Local blockade of the CD40/CD40L pathway provided little to marginal improvement in 
survival of islet xenografts [96]. Combination gene therapy using CTLA4Ig and anti-CD40Ig has also 
been applied to xenogeneic islet transplant models. AdV expression of both CD40Ig and CTLA4Ig 
results in simultaneous blockade of co-stimulation pathways, meaning this may be an acceptable 
method to induce immune tolerance [97].  
 
Whilst most of the studies of co-stimulatory molecule gene transduction have been performed with 
AdV, Fernandes and colleagues [74]  compared AdV with lentiviral gene delivery using combined 
CTLA4Ig and TGF-β, and concluded that lentivirus gave no significant advantage over AdV in terms 
of immune protection. 
 
Interleukin-4 and Interleukin-10 
Both auto- and allo-immunity are major contributing factors to islet loss post-transplantation. Skewing 
of the alloimmune response away from a TH1 and towards either a TH2 or regulatory T cell phenotype 
may improve graft survival. Transduction of pancreatic islets with two key TH2 cytokines (Interleukin 
(IL)-10 and IL-4) is a promising strategy to subvert these immune responses.  
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IL-10 is a pleiotropic cytokine affecting a wide range of immune cells including dendritic cells, down-
regulating the expression of co-stimulation molecules CD80/86 and inhibiting production of the TH1 
promoting cytokine IL-12 [98]. Pure cellular IL-10 stimulates NK cells and cytotoxic T cells, whereas 
the Epstein Barr viral IL-10 homologue has immunosuppressive properties without potential 
immunostimulation. Both systemic and local administration of IL-10 has been investigated in the 
setting of islet transplantation. Islets from transgenic mice which over express IL-10 show no survival 
advantage when compared to wild type murine islets [99]. In fact, under some circumstances, 
expression of IL-10 within the pancreatic islet has been associated with early and rapid development of 
diabetes in autoimmune-prone NOD mouse [100]. However, when viral IL-10 was introduced 
systemically using AAV in NOD mice, there was sustained suppression of autoimmune responses and 
prolongation of islet allograft survival was observed [101].  
IL-4 transduced murine islets displayed impaired metabolic function in a syngeneic model [102]. 
However other studies by Rehman and colleagues [103] found that local expression of murine IL-4 in 
islets prevented islet destruction and blocked autoimmunity, partly through regulation of T cell 
function. In a combinatorial approach, human and murine islets have been successfully transduced with 
IL-4 and IL-10 [49].  
Summary 
These studies demonstrate that the introduction of immunomodulatory genes to islets by gene therapy 
has generally not been as effective in blocking xenogeneic, allo- and auto-immune responses as the 
systemic expression of these genes. While the delivery of immunomodulatory cytokines (such as IL-4) 
that alter the local inflammatory milieu may prevent immune injury to some extent, other approaches 
that target initial immune recognition (such as CTLA4Ig) may require systemic expression to be 
effective. Therefore, islet transplantation outcomes may ultimately be enhanced by the local expression 
of a carefully selected immunomodulatory gene in conjunction with a transgene directed at another 
target. 
Anti-Apoptotic Genes 
Following transplantation, islets undergo extensive apoptosis induced by various intrinsic and extrinsic 
stimuli (see Fig. (1)). One approach to preserve β-cell mass in the early post transplant period has been 
to directly inhibit the apoptotic cascade. Some of the earliest efforts in prevention of β-cell death 
following transplantation involved inhibition of cytokine and Fas-mediated apoptosis [104-108]. 
Bcl-2 
Bcl-2 is an anti-apoptotic protein, located in the membranes of the endoplasmic reticulum, nuclear 
envelope and outer membranes of the mitochondria. The over-expression of Bcl-2 has been reported in 
various β-cell lines [109-111] and has been shown to prevent both cytokine- and hypoxia-induced cell 
death in vitro. Although this effect has not always been replicated in the whole islet [110] possibly due 
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to the requirement of the gene to be expressed in every protected cell. While some authors have 
reported a cytoprotective effect of Bcl-2 expression in vivo [112] it is thought that Bcl-2 alone is not 
sufficient to increase preservation of islet mass following transplantation [113]. 
Bcl-XL 
Bcl-XL is an anti-apoptotic member of the Bcl-2 family of proteins and is an important regulator of cell 
death. Transduction of a rat insulinoma cell line with Bcl-XL blocked both inducible nitric oxide 
synthesis (iNOS), cytokine-mediated mitochondrial changes, and subsequent apoptosis [114]. In islets, 
Bcl-XL is important for survival and deletion of Bcl-XL in pancreatic β-cells renders them abnormally 
sensitive to apoptotic stimuli in vitro and in vivo [115]. 
X-linked Inhibitor of Apoptosis Protein 
X-linked Inhibitor of Apoptosis Protein (XIAP) is another potent inhibitor of apoptosis, which works 
by blocking the activation of multiple downstream caspases [116-120]. AdV-XIAP transduction of 
human and mouse β-cell lines and whole islets confers resistance to apoptosis following exposure to 
hypoxia and cytokines in vitro [121-123]. AdV-XIAP over expression preserved both β-cell viability 
and glucose responsiveness, the latter being a critical function that ordinarily disappears very early on 
during hypoxic stress. Furthermore, an AdV-XIAP transduced β-cell line transplanted into SCID mice, 
showed successful reversal of diabetes in 3 days, compared to 21 days for control cells.  
 
In allogeneic islet transplantation, a recent study has shown that 90% of streptozotocin-induced 
diabetic animals receiving XIAP transduced islets survived up to 72 days, compared with a mean 
allograft survival of 17 days in control grafts [123]. The in vitro allogeneic response of splenocytes 
isolated from recipients of XIAP-expressing grafts 8 weeks post-transplant was similar to that seen in 
non-primed allogeneic mice, suggesting that XIAP over expression may lead to the acceptance of islet 
allografts in diabetic recipients. The mechanism behind this remains to be determined, but may involve 




Anti-apoptotic genes, such as Bcl-2, Bcl-XL and XIAP, have the potential to prevent islet cell death 
following transplantation. However, the difficulty lies in the requirement for all or most cells to express 
the gene in order to gain protection. Despite this, XIAP appears to be an effective target, as it can 
prevent apoptosis triggered by a number of stimuli in vitro and has resulted in significant in vivo islet 









Pancreatic islets are a heavily vascularized tissue, utilizing around 10% of pancreatic blood flow 
despite only making up 1% of the tissue mass. During isolation, islets are removed from the blood 
supply and become rapidly hypoxic, exacerbating early cell death and β-cell loss [124, 125]. Following 
transplantation, islets slowly revascularize, but the ultimate vascular density and function is reduced 
compared to that of native pancreatic microvasculature.  
 
During development and throughout life, islets produce a wide number of pro-angiogenic and 
angiostatic factors that maintain the dense, specialized vasculature while avoiding aberrant vessel 
production. Gene therapy, involving the delivery of pro-angiogenic genes or the inhibition of 
angiostatic factors, may be an ideal approach to improve the efficiency of engraftment and enhance the 
function of transplanted pancreatic islets. 
 
Vascular Endothelial Growth Factor 
 
Vascular Endothelial Growth Factor (VEGF) is an angiogenic factor for pancreatic islets. It is highly 
expressed during development [126] and is largely responsible for the resultant dense intra-islet 
capillary network and the maintenance of fenestrations on the endothelial cells in adulthood [127]. 
Genetic studies have suggested that VEGF may play a protective role in the development of Type I 
diabetes [128] and exogenous VEGF prevents islet death induced by serum starvation in human islets 
in vitro [129].  
 
VEGF is also essential for the revascularization of transplanted pancreatic islets [130]. Upon isolation, 
VEGF expression in islets increases, but is significantly reduced within 2–3 days post-transplant [131]. 
This impairment is further pronounced in the presence of prevailing hyperglycemia, which coincides 
with delayed and insufficient islet revascularization in diabetic mice [131-134].  
 
A number of studies have investigated VEGF in islet transplantation, either delivered as a protein or via 
gene therapy [135, 136]. Olsson and colleagues [137] found that while the culture of islets with VEGF 
improved graft revascularization one month post-transplantation, VEGF treated islets had similar or 
worse vascular engraftment compared to control islets. Zhang and colleagues [136] transferred human 
VEGF to murine islets, followed by transplantation into diabetic mice. Islet grafts with elevated VEGF 
production exhibited significantly increased microvasculature and insulin content, contributing to the 
reversal of hyperglycemia in diabetic recipient mice. Chae and colleagues [135] have demonstrated 
effective glycemic control achieved by transplanting non-viral liposome-mediated VEGF transfected 





Additional angiogenic factors 
 
While VEGF appears to be one of the most important angiogenic factors, other factors with angiogenic 
activity such as hepatocyte growth factor (HGF), fibroblast growth factor (FGF) and matrix 
metalloproteinases are also expressed naturally by islets, particularly during hypoxia [138]. The 
potential use of gene therapy to deliver these molecules to islets prior to transplantation has been 
shown in a number of studies [139, 140]. 
 
Inhibition of angiostatic factors 
 
Pancreatic islets express a number of angiostatic factors that prevent aberrant vessel formation in 
adulthood [138]. One of the most important factors in islet transplantation is thrombospondin-1 (TSP-
1) which, unlike other factors, is not downregulated by hypoxia and may contribute largely to the poor 
revascularization of islets following transplantation. At least one study has shown that the inhibition of 
TSP-1 in murine islets by siRNA transfection improves the revascularization and function of the islets 




Experimental models provide proof-of-principle that local over-expression of angiogenic molecules in 
islet grafts can stimulate graft angiogenesis and enhance islet revascularization, thereby improving the 
outcome of marginal islet transplantation with better glycemic control in diabetic mice. Angiogenic 
factors are naturally produced by islets in response to hypoxia, but their potency may be improved by 
concurrently inhibiting endogenous angiostatic factors. One concern with an angiogenic approach to 
improve transplant engraftment, is that it may hasten allorecognition and immune attack. However, in 
the clinic, islet transplants are administered under the cover of systemic immunosupression. Thus, 
improvement of revascularization may be the more important consideration.  
 
State of The Art: Islet Gene Therapy 
 
Islet transplantation is limited by a myriad of early post-transplantation factors that conspire to limit 
islet function and survival. In order to improve the outcome of islet transplantation, measures that 
promote islet engraftment and revascularization or prevent rapid apoptosis following transplantation 
need to be improved. To this end, isolated islets are ideal candidates for local gene therapy, where the 
tissue is treated ex vivo prior to transplantation. The field must focus on several areas that present 
potential intervention targets, such as immunosuppressive β-cell toxicity, apoptosis, autoimmunity 
recurrence and angiogenesis. Furthermore, the field of islet gene therapy should focus future efforts on 
identifying the optimal combination of transgenes to be delivered to isolated islets in culture, whilst 
simultaneously identifying the most effective vector that provides the least immunogenicity.  Pro-
16 
 
survival Insulin Like Growth Factor, angiogenic thioredoxin-1 and immunomodulatory IL-4 may 
represent a valid combination of targets for islet transplantation and could be investigated further.  
With the current state of gene vector technology, including the development of mutants with improved 
transduction and safety profiles, AAV vectors are likely to be the best choice for providing safe 




Gene therapy is a powerful and novel therapeutic technique, allowing modulation of the processes that 
are occurring in the local islet environment, thus avoiding potential systemic side effects. While AdV-
based vectors have been the most commonly used vectors used in preclinical studies, the improved 
safety profile of AAV vectors makes them the candidate of choice for islet transplantation. The 
successes presented by the field to date have provided important insights into the delivery of 
immunomodulatory, anti-apoptotic and angiogenic genes to islets. The advantage of secreted proteins, 
such as anti-inflammatory cytokines and angiogenic factors, is that they do not need to be expressed in 
every cell. While all three gene classes hold potential for preventing significant islet loss following islet 
transplantation, it is likely that a combinatorial approach will be required in future studies aiming to 
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